The ARFIP2 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical adenocarcinoma cell line, in which ARFIP2 has been disrupted to create a loss-of-function model. This polyclonal pool harbors heterogeneous edits across the ARFIP2 locus, providing a robust system for functional studies without clonal selection bias. Efficient CRISPR/Cas9-mediated disruption enables dissection of ARFIP2-dependent mechanisms in endosomal trafficking and actin cytoskeleton remodeling.
HeLa cells, an extensively characterized HPV-18 positive cervical adenocarcinoma line, are widely employed in cancer biology and cell signaling research. Their well-defined genetic background and robust proliferation render them an ideal host for gene editing. The epithelial origin of HeLa cells is particularly relevant for investigating cell adhesion, migration, and receptor-mediated endocytosis, all processes intimately linked to ARFIP2 function.
ARFIP2 encodes a BAR domain-containing effector of ADP-ribosylation factor (ARF) GTPases, critically involved in endosomal membrane curvature induction and intracellular trafficking. It is activated by ARF1-GTP and ARF6-GTP downstream of EGFR signaling, linking ARF activation to Rac1-dependent actin polymerization. Direct interactions with ARF1, ARF6, and Rac1 coordinate actin dynamics with endosomal sorting. ARFIP2 thereby regulates receptor recycling, cell adhesion complex formation, and integrin trafficking, modulating cell morphology and migration. Its disruption thus perturbs the intersection of endocytic and cytoskeletal pathways.
In the HeLa cell context, ARFIP2 knockout enables dissection of endosomal trafficking pathways frequently dysregulated in cancer. HeLa cells endogenously express EGFR and rely on ARF-GTPase cascades for EGFR internalization, recycling, and degradation, processes influencing oncogenic signaling. Eliminating ARFIP2 allows examination of altered EGFR trafficking, integrin recycling, and actin-mediated adhesion, offering insights into mechanisms driving cervical adenocarcinoma progression. This model is highly relevant for exploring the interplay between endosomal dynamics and tumor cell invasiveness.
The ARFIP2 Knockout HeLa Polyclonal Cells support diverse experimental applications, including quantitative transferrin uptake assays to measure endocytic rates, cell migration scratch assays to assess motile behavior, and immunofluorescence analysis of actin organization and endosomal markers. Western blotting confirms ARFIP2 knockout, co-immunoprecipitation validates disrupted ARF1/ARF6 interactions, and EGFR degradation assays probe receptor trafficking following ligand stimulation. Together, these assays enable detailed functional characterization of ARFIP2 in receptor trafficking, cytoskeletal remodeling, and cancer biology. For further information or to discuss your research needs, please contact Ascent Research.
